These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


420 related items for PubMed ID: 30151728

  • 1. Treatment of Diabetes in Patients with Heart Failure.
    Bowes CD, Lien LF, Butler J.
    Curr Cardiol Rep; 2018 Aug 27; 20(10):97. PubMed ID: 30151728
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 11; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Novel antidiabetic drugs and cardiovascular complications].
    Pareek M, Mortensen MB, Løfgren B, Nielsen ML, Olsen MH, Andersen NH.
    Ugeskr Laeger; 2018 Feb 05; 180(6):. PubMed ID: 29429477
    [Abstract] [Full Text] [Related]

  • 10. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH, Udell JA, Filion KB.
    Trends Cardiovasc Med; 2017 Apr 05; 27(3):194-202. PubMed ID: 28291655
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
    Bailey CJ, Marx N.
    Diabetes Obes Metab; 2019 Jan 05; 21(1):3-14. PubMed ID: 30091169
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 16. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R, Davis TM, Ekinci EI.
    Med J Aust; 2020 Feb 29; 212(3):133-139. PubMed ID: 31910303
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ, Newman JD.
    Curr Opin Cardiol; 2019 Nov 29; 34(6):687-692. PubMed ID: 31436559
    [Abstract] [Full Text] [Related]

  • 19. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P.
    Clin Ther; 2014 Dec 01; 36(12):2072-2079. PubMed ID: 25453730
    [Abstract] [Full Text] [Related]

  • 20. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep 01; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.